Skip to content

Study · Case report or series · n = 3 · 2024

2 results

Challenges with glucagon-like peptide-1 (GLP-1) agonist initiation: a case series of semaglutide overdose administration errors.

Wiener BG, Gnirke M, Vassallo S, Smith SW, Su MK

Clinical toxicology (Philadelphia, Pa.)1 Feb 2024Cited by 13 (Europe PMC)

PMID38470137 (opens in a new tab)DOI10.1080/15563650.2024.2322049 (opens in a new tab)PepBankPUB-38470137
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In three patients who injected semaglutide above the intended starting dose, all developed nonspecific gastrointestinal symptoms.

    In plain wordsAll three people who injected too much semaglutide at the start developed stomach and gut symptoms.

    Peptide
    Semaglutide
    Outcome
    IncreaseGastrointestinal symptoms after overdose
    Study

    n = 3

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2 mg, 2.4 mg and 1.7 mg (single doses) · injectionAs given in this study (human).

    Source sentences

    Summary
    All three of these patients developed nonspecific gastrointestinal symptoms.
    1 context sentence
    Summary · context
    Case 1: A 53-year-old man unintentionally injected semaglutide 2 mg instead of the recommended 0.1 mg. Case 2: A 45-year-old woman unintentionally injected semaglutide 2.4 mg instead of 0.25 mg. Case 3: A 33-year-old woman injected semaglutide 1.7 mg.
  2. 02HumanCase report or seriesSafety outcome

    In three patients who injected semaglutide above the intended starting dose, no patient had hypoglycemia.

    In plain wordsNone of the three people who injected too much semaglutide had low blood sugar.

    Peptide
    Semaglutide
    Outcome
    No significant changeHypoglycemia after overdose
    Study

    n = 3

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    2 mg, 2.4 mg and 1.7 mg (single doses) · injectionAs given in this study (human).

    Source sentences

    Summary
    No patient experienced hypoglycemia.
    1 context sentence
    Summary · context
    Case 1: A 53-year-old man unintentionally injected semaglutide 2 mg instead of the recommended 0.1 mg. Case 2: A 45-year-old woman unintentionally injected semaglutide 2.4 mg instead of 0.25 mg. Case 3: A 33-year-old woman injected semaglutide 1.7 mg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.